Carrillo-Esper R, Leal-Gaxiola P

Language: Spanish
References: 15
Page: 74-76
PDF size: 64.01 Kb.

Text Extraction

No abstract

REFERENCES

1. Bayram M, De Luca L, Massie B, Gheorghiade M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 2005;96:S47G-58G.

2. Dellinger RP, Levy M, Carlet J, Bion J. Surviving sepsis campaign: International guidelines for the management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.

3. Bellomo R, Chapman R, Finfer S. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomized trial. Lancet 2000;356:2139-2143.

4. Friedrich J, Adhikari N, Herridge M, Beyene J. Meta-analysis: Low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005;142:510-524.

5. Kellum J, Decker J. Use of dopamine in acute renal failure: A meta-analysis. Crit Care Med 2001;29:1526-1531.

6. De Backer D, Creteur J, Silva E, Vincent JL. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: Which is the best? Crit Care Med 2003;31:1659-1667.

7. Kam PC, Williams S, Yoong F. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia 2004;59:993-1001.

8. Carrillo ER, Carvajar RR. Vasopresina. Su aplicación en anestesiología. Rev Mex Anest 2004;27:157-166.

9. Argenziano M, Chen JM, Choudhri A. Management of vasodilatory shock after cardiac surgery: identification of predisponing factors and use of a novel pressor agent. Thorac Cardiovasc Surg 1998;116:973-980.

10. Wenzel V, Ewy G, Linder K. Vasopressin and endothelin during cardiopulmonary resuscitation. Crit Care Med 2000;28:233-235.

11. Morales D, Madigan J, Cullinane S. Reversal by vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 2000;69:102-106.

12. Beanlands R, Bach D, Raylman R, Armstrong W, Wilson V. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. J Am Coll Cardiol 1993;22:1389-1398.

13. Pastelín HG. Farmacología de los agentes inotrópicos. Arch Cardiol Mex 2002;72:S156-S162.

14. Pedemonte O. Nuevos inotropos. Rev Col Anest 1996;24:29-32.

15. Cavusoglu Y. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure. Expert Opin Pharmacother 2007;8:665-677.